FIELD: medicine.
SUBSTANCE: there are offered versions of an angiopoietin-2 (Ang-2) specific antibody and a pharmaceutical antibody composition for treatment of various diseases associated with angiopoietin-2 overexpression. Also there are described methods of inhibition, modulation and treatment of various diseases mediated by angiopoietin-2 activity. There are offered: coding nucleic acid, an expression vector and a vector-transformed cell, as well as a method for producing antibodies.
EFFECT: use of the invention ensures new high-cytotoxicity antibodies (according to ELISA analysis IC50=0,35 nM) comparable with a common antibody Ab536 that further can find application in medicine.
22 cl, 2 dwg, 11 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2011 |
|
RU2597973C2 |
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| EXPRESSION AND SECRETION SYSTEM | 2013 |
|
RU2670491C2 |
| ANTIBODIES RECOGNISING EPITOPE ON CD43 AND CEA EXPRESSED ON MALIGNANT CELLS AND METHODS FOR USING THEM | 2008 |
|
RU2528738C2 |
| BLOCKING ANTI-Dkk-1 ANTIBODIES AND APPLICATIONS THEREOF | 2010 |
|
RU2548817C2 |
| ANTIBODIES TO INTERLEUKIN-1ALPHA, AND APPLICATION METHODS THEREOF | 2013 |
|
RU2666915C2 |
| ANTIBODIES TO INTERLEUKIN-1α, AND ITS APPLICATION METHODS | 2009 |
|
RU2498998C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2009 |
|
RU2553566C2 |
| HUMAN ANTIBODIES AGAINST SEMAPHORIN 4D | 2018 |
|
RU2776443C2 |
